The effect of 3,4‐methylenedioxymethamphetamine (MDMA, ?ecstasy?) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus
Mary L. Forsling, John K. Fallon, Darshna Shah, Gary S Tilbrook, David J. Neep, Andrew T. Kicman, Andrew J. Hutt
British Journal of Pharmacology February 1, 2002 DOI: 10.1038/sj.bjp.0704502 via OpenAlex
Summary
AI-generated from the abstractMDMA and its metabolites can stimulate release of the hormones vasopressin and oxytocin from rat hypothalamic tissue in the laboratory. The metabolite HMMA (4-hydroxy-3-methoxymethamphetamine) was the most potent, increasing basal vasopressin release more than twofold and oxytocin release by about 60% at a concentration of 10 nM. MDMA itself produced smaller increases. The effect on vasopressin release was consistently greater than on oxytocin. These findings suggest that MDMA-induced hyponatraemia (low blood sodium) may result from excessive vasopressin secretion triggered by the drug or its breakdown products.
Study at a glance
| Characteristics | In vitro experimental study Peer reviewed |
|---|---|
| Population | Isolated hypothalami from male Wistar rats |
| Interventions | MDMA HMMA DHA DHMA |
| Dose | 1 μM to 100 pM |
| Topics | MDMA |
| Keywords | Vasopressin Oxytocin Endocrinology |
| Citations | 77 |
| Key finding | MDMA and its metabolites, especially HMMA, stimulate vasopressin release more strongly than oxytocin release from rat hypothalami in a dose-dependent manner. |
Abstract
Methylenedioxymethamphetamine (MDMA, “ecstasy”), widely used as a recreational drug, can produce hyponatraemia. The possibility that this could result from stimulation of vasopressin by MDMA or one of its metabolites has been investigated in vitro . Release of both oxytocin and vasopressin from isolated hypothalami obtained from male Wistar rats was determined under basal conditions and following potassium (40 m M ) stimulation. The results were compared with those obtained for basal and stimulated release in the presence of MDMA or metabolites in the dose range 1 μ M to 100 p M ( n =5 – 8) using Student's t ‐test with Dunnett's correction for multiple comparisons. All compounds tested affected neurohypophysial hormone release, HMMA (4‐hydroxy‐3‐methoxymethamphetamine) and DHA (3,4‐dihydroxyamphetamine) being more active than MDMA, and DHMA (3,4‐dihydroxymethamphetamine) being the least active. The effect on vasopressin release was greater than that on oxytocin. In the presence of HMMA the ratio test:control for basal release increased for vasopressin from 1.1±0.16 to 2.7±0.44 (s.e.m., P <0.05) at 10 n M and for oxytocin from 1.0±0.05 to 1.6±0.12 in the same hypothalami. For MDMA the ratio increased to 1.5±0.27 for vasopressin and to 1.28±0.04 for oxytocin for 10 n M . MDMA and its metabolites can stimulate both oxytocin and vasopressin release in vitro , the response being dose dependent for each drug with HMMA being the most potent. British Journal of Pharmacology (2002) 135 , 649–656; doi: 10.1038/sj.bjp.0704502